GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapidly growing market for these drugs, projected to expand from $22 billion to over $100 billion, driven by their effectiveness without requiring major lifestyle changes. We explore the competition sparked by supply shortages, with companies like Hims offering affordable alternatives, and discuss innovations like pill formulations that could make the treatments more accessible. Finally, the conversation turns to cost barriers, the potential expansion of Medicare coverage, and collaborations aimed at reducing prices to broaden access.

Download ⁠⁠Alpha⁠, an AI-powered investing watchlist.

The content of the video is for general and informational purposes only. All views presented in this show reflect the opinions of the guest and the host. You should not take a mention of any asset, be it cryptocurrency or a publicly traded security as a recommendation to buy, sell or hold that cryptocurrency or security.